Paul-Peter Tak
President and CEO, Candel Therapeutics
Paul-Peter Tak was ranked at 150 in the 2022 world ranking of top 1,000 scientists in immunology and was elected Fellow of the Academy of Medical Sciences, UK. He has previously served as senior vice president, chief immunology officer, and global development lead at GSK, where he oversaw the creation of a portfolio of new medicines. He also co-founded Sitryx Therapeutics and led Tempero Pharmaceuticals (acquired by GSK) and Kintai Therapeutics (merged with Senda Biosciences) as CEO. At Candel Therapeutics, he has brought together a world-class executive team and led the company to an IPO on the NASDAQ. Candel recently presented proof of concept for its viral immunotherapies across multiple solid tumors.
Read our 2020 interview with Paul-Peter Tak
